ArticleSexual medicine2026
Safety and efficacy of the traditional Chinese medicine chaihu guizhi ganjiang decoction combined with wendan decoction in the treatment of premature ejaculation: an open-label retrospective cohort study on Chinese men.
Article in Sexual medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chaihu Guizhi Ganjiang Decoction combined with Wendan Decoction (CGGWD) is used clinically to treat liver depression and spleen deficiency-related premature ejaculation (PE), while clinical evidence and safety are still limited. Aim: To assess the safety and efficacy of the Traditional Chinese Medicine (TCM) formula, CGGWD, in comparison with dapoxetine for PE. Methods: This retrospective study included male PE patients with liver depression and spleen deficiency treated at a prominent academic medical center (November 2021-March 2025). Patients completed a 4-week regimen, with sexual function and systemic symptoms evaluated before and after treatment. Outcomes: Outcomes were determined based on assessment of intravaginal ejaculatory latency time (IELT), Premature Ejaculation Diagnostic Tool (PEDT), Traditional Chinese Medicine Quality of Life Evaluation Scale (CQ-11D), Global Rating of Sexual Satisfaction (GRISS), and Clinical General Impression of Change (CGIC). Results: A total of 226 patients were enrolled in the study, including 165 in the CGGWD group and 61 in the dapoxetine group. After 4 weeks of treatment, the dapoxetine group showed an increase in IELT from 1.5 to 3.0 min, a decrease in PEDT scores from 13 to 9, and a reduction in GRISS scores from 37 to 28 (all Clinical Implications: The TCM formulation, CGGWD, demonstrates both safety and efficacy in the management of PE. Strengths and Limitations: This study offers the initial clinical validation of CGGWD for PE but is limited by population selection constraints, potential information bias, and unobserved confounding factors. Conclusion: For Chinese men with liver depression and spleen deficiency PE, CGGWD matches dapoxetine in efficacy but offers superior safety and systemic symptom relief, serving as a safe, effective alternative.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.